chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Nausea, Pain
Clinical narrative: Body aches; Nausea; Chills; Headache; This is a spontaneous report from a non-contactable consumer, the patient. A 62-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: tp7533) via an unspecified route of administration in the left arm on 02Apr2021 at 12:00 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. Medical history included hypertension, hypercholesterolemia, asthma, heart arrhythmia and gastroesophageal reflux disease (GERD). Concomitant medications included amlodipine (MANUFACTURER UNKNOWN), flecainide (MANUFACTURER UNKNOWN), omeprazole (MANUFACTURER UNKNOWN) and al; all from unknown dates for unknown indications. The patient received the first dose of shingles vaccine (MANUFACTURER UNKNOWN) in the left arm on 09Mar2021 within four weeks prior to the COVID-19 vaccination. The patient previously took codeine (MANUFACTURER UNKNOWN) and experienced a drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 03Apr2021 at 23:00, the patient experienced nausea, chills, body aches and headache. The adverse events did not result in doctor or other healthcare professional office/clinic visit/emergency visit. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events nausea, chills, body aches and headache were resolved on an unknown date in Apr2021.  No follow-up attempts are possible. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Rash erythematous, Urticaria
Clinical narrative: Itchy red rash; Itchy red rash; Hives on neck; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the right arm on 07Apr2021 at 12:45 (at the age of 44-year-old) as a single dose for COVID-19 immunisation. The patient previously received penicillin and experienced allergy. Concomitant medications included valaciclovir (VALACYCLOVIR) for an unspecified indication from an unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Apr2021 at 15:00, the patient experienced itchy red rash with hives on neck. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events itchy red rash with hives on neck was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Body temperature increased, Dysmenorrhoea, Menstruation delayed, Premenstrual pain
Clinical narrative: My PMS was more painful than usual; Period post vaccine was more painful than usual; My basal body temperature was unusually high during the luteal period of my menstrual cycle; And was later than usual; This is a spontaneous report from a contactable consumer, the patient. A 36-years-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the left arm on an unknown date in Apr2021 at 10:00 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies to medications, food or other products. The patient did not receive any concomitant medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On unknown date, patient basal body temperature was unusually high during the luteal period of menstrual cycle, premenstrual syndrome painful and period post vaccination was more painful than usual and was later than usual. No therapeutic measures were taken as a result of reported events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event basal body temperature was unusually high, premenstrual syndrome painful, period post vaccination and was later than usual was more painful than usual was unknown.   No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Contusion
Clinical narrative: Purple bruise on forearm; This is a spontaneous report from a contactable other healthcare professional. A 35-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via intramuscular route of administration in the left arm on 06Apr2021 at 16:30 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not receive any concomitant medications within two weeks of vaccination. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Apr2021, the patient experienced purple bruise on forearm. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event purple bruise on forearm. The clinical outcome of the event purple bruise on forearm was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Feeling abnormal, Lymphadenopathy, Mouth ulceration, Swollen tongue
Clinical narrative: Fuzzy; Dizzy feeling; Swollen lymph nodes; "Swollen tongues"; Mouth ulcers; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208) via an unspecified route of administration in the left arm on 19Mar2021 at 08:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included rheumatoid arthritis and asthma. Concomitant medications included "B-12". The patient stopped taking other medications before and after "shot (s)". The patient previously received HUMIRA and SIMPONI for unknown indication and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 19Mar2021 at 09:30, the patient felt fuzzy, dizzy feeling followed by swollen lymph nodes, "swollen tongues" and mouth ulcers. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events fuzzy, dizzy feeling, swollen lymph nodes, "swollen tongues" and mouth ulcers were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Urticaria
Clinical narrative: hives 30 minutes after the shot; This is a spontaneous report from a non-contactable consumer, the patient. A 25-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 08Apr2021 at 12:15 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medication were not reported. Patient had no allergies to food, medications or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 08Apr2021 at 12:45, the patient experienced hives 30 minutes after the shot. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of the event hives was recovered on unknown date.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Sex: F
Vaccine: COVID19
Symptoms: Pain, Vaccination site pain
Clinical narrative: injection site still sore; More so when I use my right arm more thanusual. Always aware of the pain.; This is a spontaneous report from a contactable consumer, the patient. A  non-pregnant female patient of unspecified age received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: unknown) via an unspecified route of administration in the right arm on unknown date in 2021 and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: unknown) via an unspecified route of administration in the left arm on  2021 25Mar2021 at 17:15 as a single dose for COVID-19 immunisation. Medical history included neuropathy in feet. concomitant medications were not reported. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19.  Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in 2021, the patient experienced injection site sore. The sensation was running up to neck and down to her hand and fingers. It was more so whenever she used her right arm more than usual, she was aware of the pain. It was not always severe but constantly there. She had no problem with second dose in her left arm. The patient just wanted it to get away as it was very annoying both physically and mentally. The clinical outcome of the events injection site sore and pain was unknown at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Keloid scar, Scar
Clinical narrative: Raised scar (possible keloid). Approximately 1/4 inch in diameter.; Possible keloid; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the right arm on 18Mar2021 at 07:45 (at the age of 47-year-old) as a single dose for COVID-19 immunisation. Medical history included asthma, hypertension and hypercholesterolemia and sulfonamide allergy. The patient previously took aspirin and lycopene and experienced drug allergy. The patient received medications within two weeks of vaccination which are unspecified. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 21Mar2021 the patient experienced raised scar (possible keloid), approximately 1/4 inch in diameter. No therapeutic measures were taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events raised scar (possible keloid) were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Herpes virus infection
Clinical narrative: Had a herpes outbreak; This is a spontaneous report from a contactable other healthcare professional (the patient). A 60-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN9581) via an unspecified route of administration in the arm right on 05Feb2021 at 12:45 (at the age of 60-year-old) as a single dose for COVID-19 immunisation. Medical history included low thyroid and depression postmenopausal.  Concomitant medications included levothyroxine sodium (SYNTHROID), HRT (MANUFACTURER UNKNOWN), duloxetine hydrochloride (CYMBALTA) and aluminium hydroxide, magnesium trisilicate, sodium alginate (PEPCID) for unknown indication from an unknown date. The patient previously received tetracycline (MANUFACTURER UNKNOWN) for unknown indication on an unknown date and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Mar2021 at 22:00, the patient had a herpes outbreak. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care.  Therapeutic measures were taken as a result of the event which included treatment with acyclovir (MANUFACTURER UNKNOWN). The clinical outcome of the event herpes outbreak was recovered on unknown date in 2021. The patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration on 16Mar2021 as a single dose for COVID-19 immunisation.  No follow-up attempts are needed. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Feeling hot, Pyrexia, Rash, Rash pruritic
Clinical narrative: Rash is persistent covering the left side of neck and chest; Rash is very Itchy; With in 10 mins heat feet came and went; Mild fever by night; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EW0150) via an unspecified route of administration in the left arm on 04Apr2021 at 13:00 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history included diabetes, hypothyroidism after total thyroidectomy, asthma and hypertension. The patient previously took flu vaccine (MANUFACTURER UNKNOWN), experienced vaccine allergy; soy (MANUFACTURER UNKNOWN), experienced allergy; shrimp (MANUFACTURER UNKNOWN), experienced seafood allergy; dust allergy, mold allergy and seasonal allergy. Concomitant medications included losartan (MANUFACTURER UNKNOWN), ertugliflozin pidolate (STEGLATRO), loratadine (LORATINE), Singular (Unspecified) and Statin (Unspecified) for unknown indication and on unknown date within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 04Apr2021 within 10 minutes, the patient experienced heat feet which came and went. On 04Apr2021 by night, the patient had mild fever. On 05Apr2021 next day, the patient experienced rash which was persistently covering the left side of neck and chest. The patient was not able to get rid of it, had read that it can last for 7 days and the rash was very itchy. No therapeutic measures were taken as a result of the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the event heat feet, mild fever by night, rash on left side of neck and chest and itchy rash was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site pruritus, Vaccination site rash
Clinical narrative: Itching rash at injection site; Itching rash at injection site; This is a spontaneous report from a non-contactable consumer, the patient. A 58-year-old male patient received the unknown dose number of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the left arm on 24Mar2021 at 11:45 (at the age of 58-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 05Apr2021 at 19:45 (12th day after vaccination), the patient experienced an itching rash at injection site. The clinical outcome of the events itching rash at injection site was unknown at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Pyrexia
Clinical narrative: "running fever 100.1-100.8"; This is a spontaneous report from a contactable consumer, the patient. A 54-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Er8734) via an unspecified route on 06Apr2021 at 12:30 (at an age of 54-years-old) in right arm as single dose for COVID-19 immunisation. The patient had no past medical history. Concomitant medication was not reported.  The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Er6955) via an unspecified route on 16Mar2021 in left arm at 16:00, as single dose for COVID-19 immunisation. The patient did not have any allergies to medications, food, or other products. The patient did not receive other vaccination within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. On 06Apr2021 at 23:30, approximately 12 hours after vaccination, the patient experienced "running fever 100.1-100.8" and fever continued for 24 hours. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures taken included TYLENOL. The clinical outcome of the event "running fever 100.1-100.8" was resolved on 07Apr2021 at 23:30.  No follow-up attempts are needed. No further information is expected.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Lymph node pain, Lymphadenopathy
Clinical narrative: Very swollen and painful lymph node in neck on left side; Very swollen and painful lymph node in neck on left side; This is a spontaneous report from a non-contactable consumer, the patient. A 54-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 07Apr2021 at 14:15 (at the age of 54-year-old) as a single dose for COVID-19 immunisation. Medical history included trigeminal neuralgia, hypothyroidism and penicillin allergy. Concomitant medications included oxcarbazepine (TRILEPTAL), levothyroxine (MANUFACTURER UNKNOWN and fluoxetine (MANUFACTURER UNKNOWN); all from unknown date for unknown indication. The patient had a history of allergy to penicillin, erythromycin and yeast. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 17Mar2021 at 15:15 (at the age of 54-year-old) as a single dose for COVID-19 immunisation and took Erythromycin and Yeast on unknown date for unspecified indication and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Apr2021 at 21:00 the patient experienced very swollen and painful lymph node in neck on left side. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of the event swollen and painful lymph node in neck on left side was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site mass, Vaccination site pruritus
Clinical narrative: Mild to moderate itching at the injection site; Small, slightly elevated mark/bump where the injection was given; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9262) via an unspecified route of administration in the right arm on 06Mar2021 at 13:30 (at the age of 47-years-old) and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date in Mar2021 (3 weeks after first dose) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient did not have any allergies to food, medications, or other products. The patient did not receive any medications within two weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Mar2021, ever since the first injection, the patient experienced mild to moderate itching at the injection site and there was a small, slightly elevated mark/bump where the injection was given which was ongoing. It was stated that the second dose did not leave a mark and does not itch.The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events mild to moderate itching at the injection site and small, slightly elevated mark/bump where the injection was given were not resolved at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Burning sensation, Taste disorder
Clinical narrative: Burning sensations in head; metal/chemical taste in mouth; This is a spontaneous report from a non-contactable consumer, the patient. A 49-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 01Apr2021 at 14:30 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history included arthritis and high blood pressure. Concomitant medications included atenolol (MANUFACTURER UNKNOWN), ascorbic acid (VITAMIN C), vitamin d (MANUFACTURER UNKNOWN), paracetamol (TYLENOL) and multivitamins (MANUFACTURER UNKNOWN), all taken from unknown dates for unspecified indications. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01Apr2021, immediately after vaccination, the patient experienced metal/chemical taste in mouth. On 01Apr2021 at 21:00, in the evening, the patient experienced burning sensations in head which was ongoing at the time of this report. The events resulted in doctor or other healthcare professional office/clinic visit. It was unknown if the patient received any treatment for the events. The clinical outcome of the events metal/chemical taste in mouth and burning sensations in head were not resolved at the time of report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus
Clinical narrative: I have an area of residual paresthesia on my back; Since the day after the shot that area was constantly irritated; But it burns and was constantly aware of it.; Since the day after the shot that rash area was constantly irritated, just occasionally itches; This is a spontaneous report from a contactable consumer, the patient. A 52-years-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 02Apr2021 at 17:15 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. Medical history included sudden cardiac death, thyroid cancer, small rash on my chest, a burning sensation that wrapped around to a spot on my back several years ago and repaired cardiac valves. The patient had known allergies to promethazine. Concomitant medications included propranolol (MANUFACTURER UNKNOWN), levothyroxine sodium (SYNTHROID 175), liothyronine sodium (LIOTHYRONINE) and cetirizine hydrochloride (CETIRIZ); all from unknown dates, for unknown indications and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 12Mar2021 at 18:00 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 03Apr2021, the patient experienced an area of residual paresthesia on her back, from an episode of what she thought was shingles. The patient had a small rash on her chest with a burning sensation that wrapped around to a spot on the back several years ago. Since the day after the shot that area was constantly irritated, unlike most of the time she didn't even remember it and it just occasionally itched. But it burned and the patient was constantly aware of it. No therapeutic measures were taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events I have an area of residual paresthesia on my back, the day after the shot that rash area was constantly irritated, but it burned and the patient was constantly aware of it and occasionally itched was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal discomfort, Body temperature, Chills, Headache, Myalgia
Clinical narrative: Digestive upset; symptoms of muscle aches; Chills; Intense headache; Fever peaking at 100.2; This is a spontaneous report from a contactable consumer, the patient. A 23-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ZR8734) via an unspecified route of administration in the left arm on 06Apr2021 at 17:30 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. Medical history included none. The patient had no known allergies. Concomitant medications included ethinylestradiol; levonorgestrel (ASHLYNA) from an unknown date for birth control. senegalia Senegal; ascorbic acid; betacarotene; calcium carbonate; calcium pantothenate; calcium silicate; cellulose microcrystalline; colecalciferol; croscarmellose sodium; cyanocobalamin; dextrin; dl-alpha tocopheryl acetate; ferrous fumarate; folic acid; gelatin; glucose; hypromellose; lecithin; macrogol; magnesium oxide; magnesium stearate; nicotinamide; pyridoxine hydrochloride; retinol acetate; riboflavin; silicon dioxide; starch; thiamine mononitrate; titanium dioxide; zinc oxide (ONE-A-DAY WOMEN'S) from an unknown date for an unspecified indication. The patient previously took first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 15Mar2021 at 17:45 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 07Apr2021 at 07:00 the patient experienced the symptoms of muscle aches, chills, digestive upset, intense headache, and fever peaking at 100.2 (UNSPECIFIED UNITS). The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events stomach upset, muscle ache, chills, headache, fever was recovered on an unspecified date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Digestive upset; symptoms of muscle aches; Chills; Intense headache; Fever peaking at 100.2; This is a spontaneous report from a contactable consumer, the patient. A 23-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ZR8734) via an unspecified route of administration in the left arm on 06Apr2021 at 17:30 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. Medical history included none. The patient had no known allergies. Concomitant medications included ethinylestradiol; levonorgestrel (ASHLYNA) from an unknown date for birth control. senegalia Senegal; ascorbic acid; betacarotene; calcium carbonate; calcium pantothenate; calcium silicate; cellulose microcrystalline; colecalciferol; croscarmellose sodium; cyanocobalamin; dextrin; dl-alpha tocopheryl acetate; ferrous fumarate; folic acid; gelatin; glucose; hypromellose; lecithin; macrogol; magnesium oxide; magnesium stearate; nicotinamide; pyridoxine hydrochloride; retinol acetate; riboflavin; silicon dioxide; starch; thiamine mononitrate; titanium dioxide; zinc oxide (ONE-A-DAY WOMEN'S) from an unknown date for an unspecified indication. The patient previously took first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 15Mar2021 at 17:45 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 07Apr2021 at 07:00 the patient experienced the symptoms of muscle aches, chills, digestive upset, intense headache, and fever peaking at 100.2 (UNSPECIFIED UNITS). The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events stomach upset, muscle ache, chills, headache, fever was recovered on an unspecified date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Pain in extremity
Clinical narrative: Sore arm; Extreme fatigue; This is a spontaneous report from a non-contactable consumer, the patient. A 33-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the left arm on 31Mar2021 at 14:00 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. Medical history included rhinitis, sinusitis and mild asthma. The patient received unspecified medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 31Mar2021 at 16:00, the patient experienced sore arm and extreme fatigue, arm soreness lasted about 12 hours and fatigue started about 2 hours after receiving shot and lasted for about 24 hours. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events sore arm was recovered on 01Apr2021 at 04:00 and extreme fatigue was recovered on 01Apr2021 at 16:00.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Fatigue, Headache, Myalgia
Clinical narrative: Fatigue; Headache; Worsening muscle pain; Worsening joint pain; Chills; This is a spontaneous report from a non-contactable consumer, the patient. A 28-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 07Apr2021 at 10:45 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. Medical history and other medications received within two weeks prior to vaccination were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 07Apr2021 at 23:45, the patient experienced fatigue, headache, worsening muscle pain, worsening joint pain and chills. The clinical outcome of the events fatigue, headache, worsening muscle pain, worsening joint pain and chills was unknown at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Burning sensation, Hypoaesthesia
Clinical narrative: Numbness on left side of body; burning sensation on left side of body; This is a spontaneous report from a non-contactable consumer, the patient. A 27-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE;Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose at the age of 27-year-old for COVID-19 immunisation. Medical history included covid-19. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 08Apr2021 at 19:00 the patient experienced numbness and burning sensation on left side of body. No therapeutic measures were taken as a result of the events. The events didn't result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events numbness and burning sensation on left side of body were not resolved at the time of the report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Pain, Pyrexia
Clinical narrative: Fever, chills and body aches, ~13 hours after second shot in the series.; Fever, chills and body aches, ~13 hours after second shot in the series.; Fever, chills and body aches, ~13 hours after second shot in the series.; This is a spontaneous report from a non-contactable consumer. A 54-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration on 06Apr2021 at 08:00 (at the age of 54-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration on an unknown date in 2021 as a single dose for COVID-19 immunisation. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. It was unknown whether the patient received any other vaccines within four weeks prior to the COVID-19 vaccine. On 06Apr2021 at 21:00, the patient experienced fever, chills and body aches approximately13 hours after second shot in the series. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events fever, chills and body aches was recovered on an unknown date in Apr2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Cough, Fatigue, Nausea, Pain
Clinical narrative: Pain at the injection site; Swelling at the injection site; Stiffness at the injection site; Dry cough; Fatigue; Body aches; Chills; Nausea; This is a spontaneous report from a non-contactable consumer, the patient. A 27-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150), via an unspecified route of administration in the left arm on 07Apr2021 at 08:00 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. The patient had no past medical history. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any medication within two weeks of the vaccination. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 08Apr2021 at 08:00, the patient experienced pain, swelling, stiffness at the injection site, dry cough, fatigue, nausea, chills and body aches started approximately 24 hours after the injection (as reported). The adverse events did not result in doctor or other healthcare professional office/clinic visit/ emergency visit. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events pain at the injection site, swelling at the injection site, stiffness at the injection site, dry cough, fatigue, nausea, chills and body aches was not resolved at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain, Vaccination site reaction, Vaccination site swelling
Clinical narrative: Pain at the injection site; Swelling at the injection site; Stiffness at the injection site; Dry cough; Fatigue; Body aches; Chills; Nausea; This is a spontaneous report from a non-contactable consumer, the patient. A 27-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150), via an unspecified route of administration in the left arm on 07Apr2021 at 08:00 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. The patient had no past medical history. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any medication within two weeks of the vaccination. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 08Apr2021 at 08:00, the patient experienced pain, swelling, stiffness at the injection site, dry cough, fatigue, nausea, chills and body aches started approximately 24 hours after the injection (as reported). The adverse events did not result in doctor or other healthcare professional office/clinic visit/ emergency visit. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events pain at the injection site, swelling at the injection site, stiffness at the injection site, dry cough, fatigue, nausea, chills and body aches was not resolved at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 21.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy, Pruritus, Rash
Clinical narrative: Swollen clavicle lymph nodes. Right side lymph node is protruding from the body and can visibly be seen. I; Itchy skin and large rash on back.; Itchy skin and large rash on back.; This is a spontaneous report from a contactable consumer, the patient. A 21-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the right arm on 23Mar2021 at 11:00 (at the age of 21-year-old), as a single dose for COVID-19 immunisation. Medical history was reported as no. Concomitant medications were not reported. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 29Mar2021, the patient had swollen clavicle lymph nodes, itchy skin and large rash on back. The right-side lymph node was protruding from the body and could be visibly seen. The events resulted in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the events which included treatment with steroid medication (unspecified) and diphenhydramine (BENADRYL). The clinical outcome of the events swollen clavicle lymph nodes, itchy skin and large rash on back was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site mass, Vaccination site swelling
Clinical narrative: Massive swelling and egg like bump where shot was; egg like bump where shot was; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 05Apr2021 at 15:00 (at the age of 30-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient did not have any allergies to medications, food, or other products. It was unknown if the patient was pregnant at the time of reporting. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19.  Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 05Apr2021 at 15:00, the patient experienced massive swelling and egg like bump on where the vaccine received. Patient reported that it was lasting 4 days so far. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events massive swelling and egg like bump, where the vaccine received were not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Nausea
Clinical narrative: About 30 minutes after shot while driving I got really dizzy and nauseous to the point I had to park. It lasted around an hour.; About 30 minutes after shot while driving I got really dizzy and nauseous to the point I had to park. It lasted around an hour.; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the arm left on 01Apr2021 at 11:45 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient did not receive any concomitant medications. The patient had no known allergies. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208) via an unspecified route of administration in the arm right on 11Mar2021 at 11:45 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01Apr2021 at 12:15, reportedly about 30 minutes after shot while driving the patient got really dizzy and nauseous to the point he had to park. It lasted around an hour. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of these events. The clinical outcome of the events dizzy and nauseous were recovered on 01Apr2021 at 13:15 after the duration of 1 hour.    No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Lymphadenopathy, Pyrexia, Vaccination site pain
Clinical narrative: fever; chills; sore at shot site; swollen lymph nodes under arm; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the left arm on 05Apr2021 at 08:00 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. The patient was allergic to penicillin, peanuts and shellfish. Concomitant medications included drospirenone, ethinylestradiol betadex clathrate (YAZ) taken as birth control. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021, the patient experienced fever, chills, sore at shot site and swollen lymph nodes under arm. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events fever, chills, sore at shot site and swollen lymph nodes under arm were resolving at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.